Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

about

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

Item

http://www.wikidata.org/entity/Q47153445

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

@en

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

@nl

type

Item

label

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

@en

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

@nl

prefLabel

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

@en

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

@nl

P1476

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

@en

P2093

Shin'ichi Takeda

http://www.w3.org/2001/XMLSchema#string

Takashi Okada

http://www.w3.org/2001/XMLSchema#string

Yuko Nitahara-Kasahara

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance

Intestinal microbiota composition of interleukin-10 deficient C57BL/6J mice and susceptibility to Helicobacter hepaticus-induced colitis

Interleukin-16

The chemokine system in diverse forms of macrophage activation and polarization

IL-10 inhibits cytokine production by activated macrophages

Regulatory interactions between muscle and the immune system during muscle regeneration

Do immune cells promote the pathology of dystrophin-deficient myopathies?

Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype.

Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.

P2888

s41232-016-0019-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S41232-016-0019-0

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021636554

http://www.w3.org/2001/XMLSchema#string

P698

29259687

http://www.w3.org/2001/XMLSchema#string

P932

5725653

http://www.w3.org/2001/XMLSchema#string